HC Wainwright has withdrawn a purchase for Ovid Therapeutics-Aktie fest from Investing.com

HC Wainwright has a Kaufempfehlung and a price of 3.00 US dollars for Ovid Therapeutics Inc. (NASDAQ: OVID) at.

The Einschätzung der Firma follows the presentation of Ergebnissen un Vergleichsstudie und Tieren by Ovid Therapeutics at the stattgefundenen Epilepsy Pipeline Conference. The investigation into the potential anreicherung of OV329, a GABA aminotransferase (GABA-AT) inhibitor, in medicine and the use of vigabatrin, is one of the FDA-related GABA-AT inhibitors.

The Forschung ergab, die OV329 met 48-person expositions in de Retinas, Augen of der Gehirnen von Mäusen anreicherte, was een günstiges Sicherheitsprofil hindeutet. It is a fact that this is the case, if the Vigabatrin is in the Zeitraum in those Geweben that are anreicherte. The full American Epilepsy Society study was completed in December 2024.

De ergebnisse stimmen mit früheren Studen überein, de Zeigten, ie Vigabatrin Schnell in Mäusegewebe und -plasma anreichert, einschließlich der Retina, des visuellen Kortex und des Gehirns, even bei subtherapeutische Dosen. OV329 is in phase study at therapeutic doses without proper treatment.

Zur weiteren des Sicherheitsprofils von OV329 said research here, the therapeutic dosages of drugs are no pathology of the retinal web for 45 days in the treatment of Sprague-Dawley-Rats. If you strongly believe that treatment with a therapeutic dosage will lead to a degeneration of the net zautzellen over time.

In other active cases, Ovid Therapeutics has been informed by the Entwicklung seines Prüfpräparats OV329. The main conclusion of the study was that OV329, the treatment of the GABA-AT-Enzymmangel treatment with GABA-AT-Enzymmangel, which had not yet appeared in August, had become more likely due to the risks of an ocular toxic verringert. The medicine that came out of the air as quickly as possible was a positive attitude for his Security profile. B.Riley has a clear understanding of his knowledge about the purchase of Ovid Therapeutics.

As of December 2024, we have published a number of other studies that have provided a number of years of study, with the first phase of the I phase study to be carried out for the coming years. Starting with Margaret “Meg” Alexander with Director and Chief Operating Officer, opposite Amanda Banks, MD, with the new Chief Development Officer following.

We investigated BTIG and TD Cowen in the Kauffehlungen for Ovid Therapeutics with an investigation into the potential of the phase 2 study for OV888 and the preclinical version of OV329. Oppenheimer has reabsorbed his actions from Outperform to Perform.

InvestingPro Insights

Aktuelle InvestingPro-Daten liefern zijnätzlichen Kontext zur financial situation and market performance of Ovid Therapeutics. There is a lot of information behind the financial support provided by the underlying financial support. InvestingPro-Tipps says Ovid has made money and has not had a profitable war in the last month of the month. Because it is a matter of time with the development of the economy and enterprise, investments are often made before anything is done.

There are positive aspects. Ovidius paints more money as debts in the blessing Bilanz, and his fluids when he uses the kurzfristigen Verpflichtungen. This financial support can be used for Fortsetzung seine fishing, a connection with the Entwicklung of OV329, separate from the signal.

The market reaction to Ovid’s potential war. When the company has achieved a strong Rendite gain in the three months (53.41% at InvestingPro-Daten), it has fallen a year ago in Germany (-69.27%). This fleeting mirror reflects the discourse of Ovidius Forschung as the intrinsic risks in the pharmaceutical industry widen.

For investors who like one of the many variants of Ovid Therapeutics, InvestingPro offers 10 other tips, which provide some overviews of the financial security and market position of our third-party companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.